Biohaven Pharmaceuticals
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology.
Last updated September 11, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology. It states that it is advancing multiple early-to-late-stage drug development programs in these areas, building on its legacy of transforming the treatment of migraine with Nurtec ODT (rimegepant) and Zavzpret (zavegepant). The company describes combining internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital. Vlad Coric, M.D. is listed as Chairman & Chief Executive Officer.
History
Biohaven states that it is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology. It describes building upon a legacy of transforming the treatment of migraine with Nurtec ODT (rimegepant) and Zavzpret (zavegepant), and says it is advancing multiple early-to-late-stage drug development programs in immunology, obesity, neuroscience and oncology. The company states that it has combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital. According to its website, Vlad Coric, M.D. serves as Chairman & Chief Executive Officer.
Recent events
Nurtec ODT announced as primary partner of Rick Ware Racing entry[6]
Reported:
Biohaven announced that Nurtec ODT would be the primary partner for the No. 51 Rick Ware Racing entry throughout the 2021 NASCAR Cup Series season.
Sources7 sources
- 1Clinical-stage Biopharmaceutical Company | Biohavenbiohaven.com
- 2Commitment to Patients, Winning with Science | Biohavenbiohaven.com
- 3Our People | Biohavenbiohaven.com
- 4Our Board of Directors | Biohavenbiohaven.com
- 5Biohaven Pharmaceuticalswikidata.org
- 6Nurtec ODT 宣布成为 Rick Ware Racing 赛车的主要合作伙伴prnewswire.com
- 7Biohavenâs Nurtec ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Seriestireball.com
Cite this profile: Cite the canonical profile. /brand-wiki/biohaven-pharmaceuticals · Editorial policy · How profiles are compiled